NURO - NeuroMetrix, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
-0.0300 (-2.75%)
At close: 4:00PM EDT

1.0500 -0.01 (-0.94%)
After hours: 4:29PM EDT

Stock chart is not supported by your current browser
Previous Close1.0900
Bid1.0600 x 1000
Ask1.0700 x 4000
Day's Range1.0600 - 1.0900
52 Week Range0.6000 - 1.8900
Avg. Volume121,325
Market Cap8.353M
Beta (3Y Monthly)1.41
PE Ratio (TTM)530.00
EPS (TTM)0.0020
Earnings DateOct 18, 2017 - Oct 23, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2007-03-28
1y Target Est5.00
Trade prices are not sourced from all markets
  • NeuroMetrix, Inc. (NASDAQ:NURO) Delivered A Weaker ROE Than Its Industry
    Simply Wall St.15 days ago

    NeuroMetrix, Inc. (NASDAQ:NURO) Delivered A Weaker ROE Than Its Industry

    While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why itRead More...

  • GlobeNewswire2 months ago

    NeuroMetrix Reports New Clinical Studies Published on DPNCheck

    WALTHAM, Mass., Jan. 29, 2019 -- NeuroMetrix, Inc. (Nasdaq:NURO) today reported publication of three new DPNCheck® clinical studies. DPNCheck is a point-of-care test that.

  • NeuroMetrix, Inc. (NASDAQ:NURO): A Fundamentally Attractive Investment
    Simply Wall St.2 months ago

    NeuroMetrix, Inc. (NASDAQ:NURO): A Fundamentally Attractive Investment

    I've been keeping an eye on NeuroMetrix, Inc. (NASDAQ:NURO) because I'm attracted to its fundamentals. Looking at the company as a whole, as a potential stock investment, I believe NURO Read More...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of NURO earnings conference call or presentation 24-Jan-19 1:00pm GMT

    Q4 2018 NeuroMetrix Inc Earnings Call

  • GlobeNewswire2 months ago

    NeuroMetrix Reports Q4 and Full Year 2018 Financial Results

    WALTHAM, Mass., Jan. 24, 2019 -- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter and year ended December 31, 2018. The.

  • GlobeNewswire2 months ago

    NeuroMetrix Reports Publication of Randomized Controlled Trial of Quell Wearable Pain Relief in Chronic Low Back Pain

    A total of 68 adult patients with a primary complaint of chronic low back pain were enrolled and randomized with equal probability to treatment with the Quell device (experimental group) or "treatment-as usual" (control group).  Study subjects averaged 46.2 ± 12.7 years of age and 60% were female.  All subjects reported chronic low back pain as their primary complaint.  Over half of the subjects (57%) reported multi-site pain.  All subjects used a smartphone app developed by the Pain Management Center that helps patients document and manage their pain.  Outcome measures included the Brief Pain Inventory, the Pain Catastrophizing Scale, the Pain Disability Index and the Hospital Anxiety and Depression Scale.  All subjects were given Quantitative Sensory Testing at baseline.

  • GlobeNewswire2 months ago

    Quell Reports Successful CES 2019

    Quell® 2.0 was named a CES® 2019 Innovation Awards Honoree in the Fitness, Sports and Biotech product category, recognizing the company’s innovative application of AI + neurotechnology to manage chronic pain. NeuroMetrix President and CEO, Shai Gozani was a speaker at the Digital Health Summit at CES, focusing on the continued advances in healthcare.

  • GlobeNewswire2 months ago

    NeuroMetrix, Inc. Announces Fourth Quarter 2018 Financial Results Conference Call

    WALTHAM, Mass., Jan. 15, 2019 -- NeuroMetrix, Inc. (NASDAQ: NURO) will issue its fourth quarter 2018 financial results on Thursday morning January 24, 2019. A conference call.

  • GlobeNewswire2 months ago

    Quell Named CES 2019 Innovation Awards Honoree

    NeuroMetrix, Inc. (NURO) announced that it has been named a CES® 2019 Innovation Awards Honoree for Quell® 2.0 Wearable Pain Relief Technology™ in the Fitness, Sports and Biotech product category. The announcement was made during CES 2019, which runs January 8-11, 2019 in Las Vegas, NV.  The CES Innovation Awards is an annual competition honoring outstanding design and engineering in consumer technology products. The Quell app has been totally redesigned to make it easier to use.   Quell 2.0 will be the first wearable technology to utilize machine learning to deliver unprecedented personalization for the treatment of chronic pain.  Additionally, the Quell app will include Therapy Coach to help users achieve the best possible outcomes and a new Intensive Therapy option.

  • GlobeNewswire2 months ago

    NeuroMetrix Adds Artificial Intelligence, Coaching and New Therapy Option to Quell 2.0 For Personalized Pain Relief

    NeuroMetrix Inc. (NURO) today unveiled its smartest, smallest and most powerful wearable therapeutic to date. With new features seen for the first time at CES, the recently launched Quell® 2.0 is 50% smaller, yet 20% more powerful than its predecessor.  The Company will introduce new functionality at CES that includes updates to the Quell app like coaching that helps users achieve the best possible outcomes. It also takes Pain Tech to a new level with an Intensive Therapy option and is the first wearable technology to utilize machine learning to deliver unprecedented personalization for the treatment of chronic pain.

  • GlobeNewswire3 months ago

    NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Technology

    NeuroMetrix, Inc. (NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,159,835 titled “Detecting cutaneous electrode peeling using electrode-skin impedance.” The patent covers novel methods of monitoring electrode-skin contact for safe delivery of electrical stimulation while the user is sleeping.  NeuroMetrix now has 10 issued U.S. utility patents covering the Quell® Wearable Pain Relief Technology™. "We are pleased to have received this latest patent, which covers a key technology that allows chronic pain sufferers to use Quell for pain relief at night,” said Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix. Quell is an advanced, wearable technology for treating chronic pain.

  • Benzinga3 months ago

    Analyst: NeuroMetrix Benefits From Alternative Pain Management Trend

    NeuroMetrix Inc (NASDAQ: NURO ) is a commercial-stage health care technology company with two products on the market: Quell, an OTC wearable device relying on neurostimulation technology for chronic pain ...

  • GlobeNewswire3 months ago

    NeuroMetrix to Present at Upcoming Biotech Showcase 2019 In San Francisco

    NeuroMetrix, Inc. (NURO) announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the Biotech Showcase 2019 Conference at the Hilton San Francisco Union Square on Monday, January 7, 2019 at 11:30 a.m. (Pacific). Dr. Gozani will highlight the Company's Quell® Wearable Pain Relief Technology™ and provide an update on the Company’s business activities. Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and the life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences.

  • Simply Wall St.3 months ago

    Is NeuroMetrix, Inc.’s (NASDAQ:NURO) CEO Pay Fair?

    In 1997 Shai Gozani was appointed CEO of NeuroMetrix, Inc. (NASDAQ:NURO). First, this article will compare CEO compensation with compensation at similar sized companies. Then we'll look at a snap Read More...

  • ACCESSWIRE3 months ago

    Today's Research Reports on Trending Tickers: NeuroMetrix and Moleculin

    NEW YORK, NY / ACCESSWIRE / December 12, 2018 / NeuroMetrix and Moleculin were both up almost 19% in Tuesday’s trading session. Traders were gearing up for Moleculin’s conference call today discussing a recent discovery of a use of one of its molecules for cancer treatment while NeuroMetrix announced an update on its strategic collaboration with GSK Consumer Healthcare. NeuroMetrix, Inc. shares were up nearly 19% on almost 1.7 million shares traded on Tuesday.

  • GlobeNewswire3 months ago

    NeuroMetrix Reports Agreement with GSK Healthcare on 2019 Quell Joint Development Program and Modification to Strategic Collaboration

    Under terms of the collaboration entered into in the first quarter of 2018, the parties committed to co-fund future development of Quell® technology beginning in 2019, subject to agreement on an annual program of product initiatives. The Company reported that agreement has been reached on the 2019 development program and it will commence in January 2019.

  • GlobeNewswire4 months ago

    NeuroMetrix Announces DPNCheck Collaboration Agreement with Fukuda Denshi for Japan Market  

    WALTHAM, Mass., Nov. 15, 2018 -- NeuroMetrix, Inc. (Nasdaq:NURO), announced today that it had executed a distribution agreement with Fukuda Denshi Co. Ltd. for DPNCheck®, the.

  • GlobeNewswire4 months ago

    Report: Developing Opportunities within NeuroMetrix, Sunesis Pharmaceuticals, Siga Technologies, NexPoint Residential Trust, Frequency Electronics, and Horizon Technology Finance — Future Expectations, Projections Moving into 2018

    NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of NURO earnings conference call or presentation 17-Oct-18 12:00pm GMT

    Q3 2018 NeuroMetrix Inc Earnings Call

  • ACCESSWIRE5 months ago

    NeuroMetrix, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / October 17, 2018 / NeuroMetrix, Inc. (NASDAQ: NURO ) will be discussing their earnings results in their 2018 Third Quarter Earnings to be held on October 17, 2018 at 8:00 AM ...